$AZN · ASTRAZENECA PLC
AstraZeneca reported Q3 2026 Total Revenue of $16.209B (+7% actual, +7% CER) and Core EPS of $2.79 (+17% actual, +19% CER). 9M Total Revenue reached $46.881B (+8% actual, +7% CER) with Core EPS of $8.00 (+14% CER). FY 2026 guidance was reaffirmed: mid-to-high single-digit revenue growth and low double-digit Core EPS growth at CER. The company also announced a $2B equity investment in Summit Therapeutics and a new Reshaping for Sustainable Growth program with up to $2B in restructuring costs targeting $1.5B in annualized savings.
- Total Revenue $16.209B in Q3, +7% actual and +7% CER, with double-digit Oncology growth (+17% CER)
- Core EPS of $2.79 in Q3, +17% actual and +19% CER; 9M Core EPS $8.00, +14% CER
- Oncology Product Revenue hit $7.765B in Q3 (+17% CER), led by Tagrisso ($2.087B), Imfinzi ($1.990B), and Enhertu ($969M)
- FY 2026 guidance reaffirmed: mid-to-high single-digit revenue growth and low double-digit Core EPS growth at CER
- Announced $2B equity investment in Summit Therapeutics (~12% stake) and a new RSG restructuring program costing up to $2B for $1.5B annualized savings by 2029
Extended-hours trading shows AZN at $183.65, +5.30% vs the regular close of $174.40, indicating a strong positive reaction to the Q3 beat and reaffirmed guidance. The $270B market-cap pharma giant's double-digit Core EPS growth and robust oncology pipeline readouts are driving the after-hours bid.
AstraZeneca's Q3 beat, reaffirmed guidance, and disclosure of 12 positive Phase III readouts with >$10B peak revenue potential confirm it as the most catalyst-dense mega-cap pharma name heading into 2027.
AstraZeneca's 7% CER revenue growth and 14% Core EPS growth outpaces many large-cap pharma peers facing steeper patent cliffs. The 12 positive Phase III readouts year-to-date with >$10B peak revenue potential and a 2027 catalyst pipeline worth >$20B position AZN as the sector's most catalyst-rich mega-cap.
Farxiga faces accelerating generic erosion (US LoE in Q2 2026, China VBP in Q1 2026) with 9M revenue down 12% actual; Brilinta declined 61% on US/Europe generics. China VBP and a slowing EGFR TKI market pressured Tagrisso and Lynparza. The RSG restructuring program carries up to $2B in one-time costs through 2029.